Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Briacell Therapeutics Corp (BCT.VN)

Briacell Therapeutics Corp (BCT.VN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX Venture]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX Venture]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 168,676
  • Shares Outstanding, K 15,913
  • Annual Sales, $ 0 K
  • Annual Income, $ -428 K
  • 60-Month Beta 1.44
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 2.38
Trade BCT.VN with:
  • Price/Earnings ttm 28.59
  • Earnings Per Share ttm 0.29
  • Most Recent Earnings -0.16 on N/A
  • Next Earnings Date 12/29/21
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Price Performance

See More
Period Period Low Period High Performance
1-Month
9.150 +15.85%
on 12/13/21
15.750 -32.70%
on 12/01/21
-2.090 (-16.47%)
since 11/30/21
3-Month
8.730 +21.42%
on 10/06/21
15.750 -32.70%
on 12/01/21
+0.290 (+2.81%)
since 09/30/21
52-Week
3.500 +202.86%
on 05/19/21
15.750 -32.70%
on 12/01/21
+5.050 (+90.99%)
since 12/30/20

Most Recent Stories

More News
BriaCell Therapeutics Corp. Announces Results of 2022 Annual and Special Meeting of Shareholders

NEW YORK and VANCOUVER, British Columbia, Jan. 19, 2022 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or...

BCTXW : 2.30 (+1.29%)
BCTX : 5.07 (+13.42%)
BCT.VN : 10.600 (-3.81%)
BCT.TO : 6.50 (+13.04%)
BriaCell to Uplist and Trade on the Toronto Stock Exchange from TSX Venture Exchange under 'BCT'; Remains 'BCTX' on Nasdaq

BERKELEY, Calif. and VANCOUVER, British Columbia, Dec. 29, 2021 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT)...

BCT.VN : 10.600 (-3.81%)
BCTXW : 2.30 (+1.29%)
BCTX : 5.07 (+13.42%)
BCT.TO : 6.50 (+13.04%)
BriaCell Summarizes Clinical Data Poster Presented at the 2021 San Antonio Breast Cancer Symposium®

NEW YORK and VANCOUVER, British Columbia, Dec. 09, 2021 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX-V:BCT) (“BriaCell” or...

BCTXW : 2.30 (+1.29%)
BCTX : 5.07 (+13.42%)
BCT.VN : 10.600 (-3.81%)
BriaCell Adds Mary Crowley Cancer Research Center as a Clinical Trial Site for its Phase I/IIa Breast Cancer Study

NEW YORK and VANCOUVER, British Columbia, Nov. 18, 2021 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX-V:BCT) (“BriaCell” or...

BCTXW : 2.30 (+1.29%)
BCTX : 5.07 (+13.42%)
BCT.VN : 10.600 (-3.81%)
BriaCell Announces Update on Previously Announced Securities Buyback Program and Participation at Upcoming Conferences

BERKELEY, Calif. and VANCOUVER, British Columbia, Nov. 12, 2021 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX-V:BCT)...

BCTXW : 2.30 (+1.29%)
BCTX : 5.07 (+13.42%)
BCT.VN : 10.600 (-3.81%)
BriaCell Adds Pioneering Immunologist and Cancer Immunotherapy Expert, Suzanne Ostrand-Rosenberg, Ph.D., to its Scientific Advisory Board

NEW YORK and VANCOUVER, British Columbia, Nov. 05, 2021 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX-V:BCT) (“BriaCell” or...

BCTXW : 2.30 (+1.29%)
BCTX : 5.07 (+13.42%)
BCT.VN : 10.600 (-3.81%)
BriaCell Appoints Renowned Pharmaceutical Veteran Jane Gross, Ph.D. to its Board of Directors

NEW YORK and VANCOUVER, British Columbia, Nov. 02, 2021 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX-V:BCT) (“BriaCell” or...

BCTXW : 2.30 (+1.29%)
BCTX : 5.07 (+13.42%)
BCT.VN : 10.600 (-3.81%)
BriaCell Therapeutics CEO Emphasizes Recent Key Developments in Audio Interview with SmallCapVoice.com

AUSTIN, Texas, Sept. 23, 2021 (GLOBE NEWSWIRE) -- SmallCapVoice.com Inc. (“SCV”) announces the availability of a new interview with Dr. Bill Williams, CEO of BriaCell Therapeutics Corp. (Nasdaq:...

BCTX : 5.07 (+13.42%)
BCTXW : 2.30 (+1.29%)
BCT.VN : 10.600 (-3.81%)
BriaCell Announces TSXV Acceptance of Normal Course Issuer Bid

BERKELEY, Calif. and VANCOUVER, British Columbia, Sept. 22, 2021 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX-V: BCT) (“BriaCell” or the “Company”) , a clinical-stage...

BCTX : 5.07 (+13.42%)
BCTXW : 2.30 (+1.29%)
BCT.VN : 10.600 (-3.81%)
BriaCell to Present at the Benzinga Healthcare Small Cap Conference September 29-30

BERKELEY, Calif. and VANCOUVER, British Columbia, Sept. 16, 2021 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX-V: BCT) (“BriaCell” or the “Company”) , a clinical-stage...

BCTX : 5.07 (+13.42%)
BCTXW : 2.30 (+1.29%)
BCT.VN : 10.600 (-3.81%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Buy with a Weakest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Key Turning Points

3rd Resistance Point 11.383
2nd Resistance Point 11.227
1st Resistance Point 10.913
Last Price 10.600
1st Support Level 10.443
2nd Support Level 10.287
3rd Support Level 9.973

See More

52-Week High 15.750
Fibonacci 61.8% 11.070
Last Price 10.600
Fibonacci 50% 9.625
Fibonacci 38.2% 8.179
52-Week Low 3.500

See More

Business Summary

BriaCell Therapeutics Corp is an immuno-oncology focused biotechnology company developing targeted and safe approaches for the management of cancer. BriaCell, in collaboration with Incyte Corp., is conducting a Phase I/IIa clinical trial of Bria-IMT, its lead candidate, in a Combination Study with Incyte...

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar